<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BackgroundWe studied the overlap between the major (epi)genomic events microsatellite instability (MSI), the CpG island methylator phenotype (CIMP) and <z:mp ids='MP_0008866'>chromosomal instability</z:mp> (CIN) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), and whether specific (epi)genotypes were associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo>.Patients and methodsMolecular analyses using <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> DNA were successful in 509 CRC cases identified within the Netherlands Cohort Study in the period 1989-1993 </plain></SENT>
<SENT sid="1" pm="."><plain>Follow-up for the vital status until May 2005 was 100%.ResultsMSI (12.6%), CIMP-only (5.3%), CIMP + CIN (13.4%), CIN-only (58.2%) and triple-negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (10.6%) differed significantly regarding <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> localization, differentiation grade, initial adjuvant therapy (AT) use and genetic characteristics (P â‰¤ 0.03) </plain></SENT>
<SENT sid="2" pm="."><plain>CIMP-only, CIMP + CIN and triple-negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, compared with CIN-only <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, were significantly associated with a 3.67, 2.44 and 3.78-fold risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> after 2-year follow-up (95% confidence intervals, CIs, 1.70-7.91, 1.35-4.41 and 1.97-7.25, respectively), but not after late follow-up </plain></SENT>
<SENT sid="3" pm="."><plain>MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were borderline significantly associated with a 0.40-fold risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> after late follow-up (95% CI 0.15-1.03).Conclusion(s)This is the first study to show that specific (epi)genotypes may hold a differential prognostic value that may vary over time </plain></SENT>
<SENT sid="4" pm="."><plain>Although no specific treatment data were available, an explanation for the differential findings over time might be that (epi)genotypes modify therapy response </plain></SENT>
</text></document>